Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.

Condition or disease	Intervention/treatment	Phase
Crohn's Disease	Biological: Placebo matching with BMS-945429; Biological: BMS-945429	Phase 2

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	72 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Study Start Date :	June 2012
Actual Primary Completion Date :	December 2013
Actual Study Completion Date :	December 2013

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Induction Cohort: Placebo matching with BMS-945429	Biological: Placebo matching with BMS-945429; Injection, Intravenous (IV), 0 mg, Day One Only, One Day; Biological: Placebo matching with BMS-945429; Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
Experimental: Induction Cohort: BMS-945429 (600 IV/200 SC mg)	Biological: Placebo matching with BMS-945429; Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day; Biological: BMS-945429; Injection, Intravenous (IV), 600 mg, Day One Only, One Day; Biological: BMS-945429; Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
Experimental: Induction Cohort: BMS-945429 (300 IV/100 SC mg)	Biological: Placebo matching with BMS-945429; Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day; Biological: BMS-945429; Injection, Intravenous (IV), 300 mg, Day One Only, One Day; Biological: BMS-945429; Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
Experimental: Induction Cohort: BMS-945429 (150 IV/100 SC mg)	Biological: Placebo matching with BMS-945429; Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day; Biological: BMS-945429; Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day; Biological: BMS-945429; Injection, Intravenous (IV), 150 mg, Day One Only, One Day
Experimental: Induction Cohort: BMS-945429 (400 SC/200 SC mg)	Biological: Placebo matching with BMS-945429; Injection, Intravenous (IV), 0 mg, Day One Only, One Day; Biological: BMS-945429; Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day; Biological: BMS-945429; Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
Experimental: Maintenance Cohort: Placebo matching with BMS-945429	Biological: Placebo matching with BMS-945429; Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
Experimental: Maintenance Cohort: BMS-945429 (100 SC mg)	Biological: BMS-945429; Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
Experimental: Maintenance Cohort: BMS-945429 (200 SC mg)	Biological: BMS-945429; Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
Experimental: Open Label Cohort: BMS-945429 (200 SC mg)	Biological: BMS-945429; Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Proportion of subjects with clinical remission as measured by the Crohn's Disease Activity Index [ Time Frame: At 8 weeks during the Induction Period ]

Secondary Outcome Measures :

1. Proportion of subjects with clinical response during Induction Period [ Time Frame: Week 8 ]
2. Change from baseline of Inflammatory Bowel Disease Questionnaire (IBDQ) and Short Form-36 (SF-36) [ Time Frame: Baseline (Week 0), Week 8 and Week 12 ]
3. Safety during the Induction Period as measured by adverse events, vital signs, physical examinations and safety lab values [ Time Frame: Up to Week 12 ]
4. Immunogenicity during the Induction Period will be assessed based on levels of anti-BMS-945429 antibodies [ Time Frame: Up to Week 12 ]
5. Steady-state trough concentration (Cmin) of BMS-945429 during the Induction Period [ Time Frame: Week 4, Week 8, Week 12 ]
6. Observed maximum concentration (Cmax) of BMS-945429 during the Induction Period [ Time Frame: Week 0 and Week 4 ]
7. Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)] of BMS-945429 during the Induction Period [ Time Frame: Week 0, Week 4, Week 8 ]

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Confirmed Crohn's Disease diagnosis via radiology, endoscopy or histology within prior 12 months. Diagnosed for at least 3 months
• Active Disease with Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450
• Failed conventional therapy or steroid dependent

Exclusion Criteria:

• Diagnosed/clinical findings of Ulcerative Colitis (UC), indeterminate colitis, non colonic/ileal disease
• Stricture/stenosis, Stoma, proctocolectomy, subtotal colectomy, ileorectal anastomosis
• History of diverticulitis, or evidence of Gastrointestinal (GI) perforations

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

  Show 56 Study Locations

Sponsors and Collaborators

Vitaeris INC

Investigators

Study Director:	Bristol-Myers Squibb	Bristol-Myers Squibb

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

BMS clinical trial educational resource 

Investigator Inquiry form 

FDA Safety Alerts and Recalls 

Responsible Party:	Vitaeris INC
ClinicalTrials.gov Identifier:	NCT01545050 History of Changes
Other Study ID Numbers:	IM133-005; 2011-004763-72 ( EudraCT Number )
First Posted:	March 6, 2012
Last Update Posted:	April 24, 2018
Last Verified:	April 2018

Additional relevant MeSH terms:

Crohn Disease; Inflammatory Bowel Diseases; Gastroenteritis	Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases